EverCyte

EverCyte is a Vienna-based biotech firm leveraging human telomerase (hTERT) immortalization to create standardized, long-lived human cell lines that mimic primary cell function. Its core business revolves around two pillars: providing these cells and derived extracellular vesicles as products for research, and offering contract services in cell line development, drug screening, and gene editing. The company positions itself as an enabler for more predictive preclinical testing and scalable production of therapeutic EVs, operating primarily as a B2B platform and service provider within the regenerative medicine and cell therapy sectors.

Proprietary platform for creating standardized human cell lines via hTERT-mediated telomerization, combined with reprogramming and CRISPR/Cas9 gene editing. Used to develop in vitro test systems and cell factories for extracellular vesicle (EV) production.

Operates in a competitive space including large life science tool companies (e.g., Lonza, ATCC), specialized iPSC companies, and numerous EV-focused startups. Differentiation lies in the specific combination of primary-like telomerized cells, a focus on MSCs and EVs, and an integrated service model.